RANIRani Therapeutics Holdings,...

Nasdaq ranitherapeutics.com


$ 6.35 $ 0.00 (0 %)    

Thursday, 02-May-2024 15:59:05 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 6.37
$ 6.28
$ 6.29 x 100
$ 6.40 x 100
$ 6.24 - $ 6.37
$ 1.82 - $ 8.75
324,125
na
162.47M
$ 0.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-20-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-16-2021 09-30-2021 10-Q
11 09-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 equifax-reports-weak-sales-joins-synovus-financial-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday.

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 netflix-to-rally-over-15-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 canaccord-genuity-maintains-buy-on-rani-therapeutics-hldgs-lowers-price-target-to-9

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target...

 hc-wainwright--co-maintains-buy-on-rani-therapeutics-hldgs-lowers-price-target-to-12

HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the pr...

 rani-therapeutics-hldgs-q4-2023-gaap-eps-027-beats-031-estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate ...

 earnings-scheduled-for-march-20-2024

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per s...

 wedbush-reiterates-outperform-on-rani-therapeutics-hldgs-maintains-8-price-target

Wedbush analyst Andreas Argyrides reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform and maintains $8 price ...

 rani-therapeutics-announces-topline-results-from-phase-1-study-of-oral-anti-interleukin-1223-antibody

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events -- Celltrion has...

 rani-therapeutics-announces-preclinical-pharmacodynamic-data-on-transenteric-delivery-of-glp-1-incretin-triagonist

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –- P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION